Abstract
The development of Histone Deacetylase (HDAC) inhibitors has, until recently, principally been driven by their potential as anti-cancer agents. However, there is emerging evidence that HDAC inhibitors could have utility in the treatment of chronic immune and inflammatory disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, airway hyperresponsiveness and organ transplant rejection. Here we discuss the merits of various, structurally-distinct HDAC inhibitors as potential anti-inflammatory therapeutics and provide examples of the novel medicinal chemistry approaches being undertaken to realize HDAC as a druggable target in this clinical setting.
Keywords: Histone deacetylases, inhibitors, inflammation, immune disease, FK228, deacetylases, multiple sclerosis, rheumatoid arthritis, psoriasis, histones, nuclear proteins, T-cell lymphoma, (FDA), GM-CSF, TNFα, TGFβ, (MMPs), iNOS, IL-1β, IFN-, (Tregs), Cyclosporin-A, IL-2, (ZEB), (CtBP), CD4+ T, FR276457, (GVHD), (T-cell depletion), phosphorylation, (IBD), (SLE), CD28, RASFs, KBH-A42, Trichostatin-A, Vorinostat, chemokines, CTCL
Current Drug Targets
Title: Histone Deacetylase Inhibitors: New Promise in the Treatment of Immune and Inflammatory Diseases
Volume: 11 Issue: 11
Author(s): Stephen J. Shuttleworth, Sarah G. Bailey and Paul A. Townsend
Affiliation:
Keywords: Histone deacetylases, inhibitors, inflammation, immune disease, FK228, deacetylases, multiple sclerosis, rheumatoid arthritis, psoriasis, histones, nuclear proteins, T-cell lymphoma, (FDA), GM-CSF, TNFα, TGFβ, (MMPs), iNOS, IL-1β, IFN-, (Tregs), Cyclosporin-A, IL-2, (ZEB), (CtBP), CD4+ T, FR276457, (GVHD), (T-cell depletion), phosphorylation, (IBD), (SLE), CD28, RASFs, KBH-A42, Trichostatin-A, Vorinostat, chemokines, CTCL
Abstract: The development of Histone Deacetylase (HDAC) inhibitors has, until recently, principally been driven by their potential as anti-cancer agents. However, there is emerging evidence that HDAC inhibitors could have utility in the treatment of chronic immune and inflammatory disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, multiple sclerosis, systemic lupus erythematosus, airway hyperresponsiveness and organ transplant rejection. Here we discuss the merits of various, structurally-distinct HDAC inhibitors as potential anti-inflammatory therapeutics and provide examples of the novel medicinal chemistry approaches being undertaken to realize HDAC as a druggable target in this clinical setting.
Export Options
About this article
Cite this article as:
J. Shuttleworth Stephen, G. Bailey Sarah and A. Townsend Paul, Histone Deacetylase Inhibitors: New Promise in the Treatment of Immune and Inflammatory Diseases, Current Drug Targets 2010; 11 (11) . https://dx.doi.org/10.2174/1389450111009011430
DOI https://dx.doi.org/10.2174/1389450111009011430 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Combined Dyslipidemia: Should the Focus be LDL Cholesterol or Atherogenic Dyslipidemia?
Current Pharmaceutical Design The Role of T-Helper Cells in Atherosclerosis
Cardiovascular & Hematological Agents in Medicinal Chemistry Drug Targets in Severe Acute Respiratory Syndrome (SARS) Virus and other Coronavirus Infections
Infectious Disorders - Drug Targets Cysteine-Rich Mini-Proteins in Human Biology
Current Topics in Medicinal Chemistry Molecular Mechanisms Regulating Matrix Metalloproteinases
Current Topics in Medicinal Chemistry Thymoquinone Shows the Diverse Therapeutic Actions by Modulating Multiple Cell Signaling Pathways: Single Drug for Multiple Targets
Current Pharmaceutical Biotechnology Therapeutic Implications of Gene Deletion of Ligands and Receptors of Members of TNF Superfamily
Medicinal Chemistry Reviews - Online (Discontinued) High Performance Liquid Chromatographic Approaches to Mass Spectrometry Based Metabolomics
Current Metabolomics Wnt Signaling and Cell-Matrix Adhesion
Current Molecular Medicine Regulation of Multidrug Resistance by Pro-Inflammatory Cytokines
Current Cancer Drug Targets Flavonoids: Prospective Drug Candidates
Mini-Reviews in Medicinal Chemistry Fcγ Receptor 1 (CD64), a Target Beyond Cancer
Current Pharmaceutical Design Atherosclerotic and Non-Atherosclerotic Coronary Heart Disease in Women
Current Medicinal Chemistry “Multi-component Reactions : Emerging Chemistry in Drug Discovery” ‘From Xylocain to Crixivan’
Current Medicinal Chemistry Current Status of Complementary and Alternative Medicine in the Treatment of Rheumatic Disease Pain
Current Rheumatology Reviews Histone Deacetylase Inhibitors In Inflammatory Disease
Current Topics in Medicinal Chemistry Role, Metabolism, Chemical Modifications and Applications of Hyaluronan
Current Medicinal Chemistry Drug Induced Cutaneous Manifestations due to Treatment of Gastrointestinal Disorders
Current Drug Metabolism Protective Effects of Curcumin Against Nephrotoxic Agents
Cardiovascular & Hematological Disorders-Drug Targets Current Opinions and Perspectives on the Role of Immune System in the Pathogenesis of Parkinson's Disease
Current Pharmaceutical Design